SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly earnings report is the dominant focus, with traders watching guidance, subscriber engagement and advertising growth amid concerns about slowing growth, content quality and competition; recent leadership changes and layoffs add to the debate. Bulls see pessimism as overdone, while bears expect further weakness, leaving sentiment sharply divided ahead of the report.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Heavy buying and a sharp rebound have fueled speculation about a potential buyout or imminent company news, but neither has been confirmed. The main catalyst in discussion is the Phase 3 REGAL trials pending final analysis after the last disclosed count of 78 of 80 events; bullish traders read the CEOs optimistic anniversary post as encouraging, while skeptics point to the lack of new trial news and caution that the move may reflect trading activity.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas rally is largely tied to anticipation of the detailed Phase 3 melanoma cancer-vaccine results with Merck at ESMO, after positive topline results sparked a major revaluation. Traders are split between momentum-driven optimism about the broader oncology platform and concerns that expectations and valuation are stretched, with some anticipating a sell-the-news pullback.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

SRPTs sharp rebound above recent technical levels has traders discussing a possible breakout and short covering, though no specific new catalyst is confirmed. Bulls are also anticipating DM1 and FSHD siRNA readouts, while some caution that the move may reflect broader biotech strength or prove temporary.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is under pressure amid broader concerns about neocloud funding, debt, and whether AI infrastructure spending will generate adequate returns; co-CEO Daniel Roberts comments that the data centers were cash-funded and customer prepayments help cover GPU costs are being cited as reassurance. Traders are split between viewing the selloff as an oversold buying opportunity and expecting further downside, with many frustrated that IREN has lagged peers.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GMs shares fell despite a third-quarter earnings beat and a new buyback, as traders focused on the narrowed full-year profit outlook and unchanged midpoint. The reaction is split between dip buyers citing cash generation and repurchases, and bears who see the outlook and softer sales as outweighing those positives.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE Aerospaces quarterly beat and raised 2026 outlook are being overshadowed by a sharp selloff. Traders debate whether it is a sell-the-news reaction after expectations ran high or a response to rising costs, weaker cash conversion and an insurance loss, while some point to strong orders as evidence demand remains robust.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports Phase 2 RAP-219 trial in bipolar mania met its primary and secondary endpoints, driving attention alongside analyst upgrades. Traders are divided over the modest placebo-adjusted symptom improvement and concerns about discontinuations and agitation, with some viewing the data as a positive proof of concept and others arguing the rally may fade.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriad Genetics agreement to sell its prenatal testing business to Labcorp has driven the sharp share move, with traders viewing the cash sale as a balance-sheet and strategic reset. The community is split between bullish momentum and concern that divesting a revenue-generating unit could leave the remaining business smaller and debt pressures unresolved.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA is drawing attention as traders watch for Q3 results to confirm continued growth in high-margin ASCENIV amid weakness in BIVIGAM, with the recent move around its 200-day average adding to the recovery discussion. Bulls point to ASCENIV and share repurchases, while skeptics cite uncertain growth and lingering concerns from the Culper short report and related litigation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tom Lee’s Ethereum Year-End Call Is Now Half Of What He Called ‘Conservative’ Last Month, But He Expects ‘Monster Moves’ In The Crypto Industry

Cryptocurrency

Tom Lee tied the nearer call to BTC, saying ETH should reach about $7,500 if Bitcoin hits $100,000.


BMNR Stock Gains Alongside Ethereum After Tom Lee's BitMine Makes One Of Its Smallest Ethereum Purchases Ever

Equity

Chairman Tom Lee said the company carried out what he described as the largest crypto treasury equity buyback. 

BMNR Stock Forms Golden Cross For First Time Since Bitmine’s Ethereum Pivot Rally 

The last time the 50-day line crossed above the 200-day was more than a year ago, when the company pivoted to buying Ethereum. 


Tom Lee Says ETH Could Top $10,000 In The Next 12 Months, Calls Arthur Hayes' Year-End Target 'Conservative'

Tom Lee said crypto treasury companies could ramp up buying over the next 12 to 18 months, potentially tightening ETH supply. 

Tom Lee Says ‘Stay Tuned’ As Bitmine Nears 5% Ethereum Goal, Hints At What’s Next

Tom Lee-backed Bitmine now holds 4.9% of the supply of all the Ethereum in circulation.


Tom Lee Says Crypto Is A 'Huge Winner' As Banks Move Toward Tech-Style Valuations, While Dan Ives Calls AI A 'Two-Horse Race'

Fundstrat picked JP Morgan as a core buy and Robinhood, Galaxy Digital, and Riot Platforms as bottom five recommendations, cautious on crypto-sensitive stocks.

Tom Lee's BMNR Adds 1 BTC, Expands ORBS Stake By $7M Amid Ethereum Buying Spree

BitMine expanded its crypto and equity holdings while keeping its focus on building a 5% stake in Ethereum. 

BMNR Stock Dips Even As Its Latest Ethereum Buy Leaves It Just 0.1% From Its 'Alchemy Of 5%' Goal

Bitmine chairman Tom Lee said BMNR stock was the fourth-best performer in the Russell 1000, setting “the stage for institutions to add to their crypto holdings.”


BitMine Makes Biggest Weekly Ethereum Purchase Since June, Adding Over 50K ETH To Its Stash

BitMine stepped up its Ethereum buying as it moved close to controlling 5% of ETH’s total supply.


Tom Lee-Led BitMine Reportedly Scoops Up $48.89 Million Of Ethereum During Crypto’s ‘AI Downstream’ Story

Bitcoin dominance remains above 60%, which a crypto commentator says leaves a broader altcoin rotation unconfirmed.


ETF Opportunities Trust - T-REX 2X Long BMNR Daily Target ETF

Bearish Sentiment

<ul class="summary-bullets"><li>BitMine Immersion Technologies chairman Tom Lee said <a class="mention" data-mention="$ETH.X" data-symbol-id="ETH.X" href="https://stocktwits.com/symbol/ETH.X" target="_blank">Ethereum</a> should top $5,000 by year-end, in Singapore on Friday.</li><li>That was half the $10,000 year-end figure Lee called "conservative" when he also said Ethereum would trade "much higher" than that level within 12 months.</li><li>His cycle target came down too, to "25,000 or 50,000 per token" from an illustrative $62,000 nine days earlier.</li></ul><p>Ethereum (ETH) held above $2,400 on Saturday after BitMine Immersion Technologies (BMNR) chairman Tom Lee said the token should top $5,000 by year-end, half the level he called a “conservative target” more than a week ago.</p><p>Speaking at&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.youtube.com/watch?v=xyGoVLlpnDY">Token 2049</a> in Singapore on Friday, Lee, who is also co-founder and head of research at Fundstrat, tied the call to Bitcoin (BTC). If Bitcoin climbs to $100,000, he said, Ethereum should trade around $7,500. That was a step down from what he called FLOP Labs’ CEO Arthur Hayes’ $10,000 year-end prediction for&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/tom-lee-says-eth-could-top-10-000-in-the-next-12-months-calls-arthur-hayes-year-end-target-conservative/cZMF2mYRBha">Ethereum “conservative</a>,” last month.</p><p>Then, with Ethereum near $2,670, he said the token would see “much higher prices than 10,000” within 12 months. To support his point, Lee said, “Think Arthur's conservative in the sense that you know in the past cycles Ethereum has gone up 50 times to 200 times.”</p><p>On Friday, the cycle number was lower too. Ethereum “could easily be 25,000 or 50,000 per token,” he said.&nbsp;</p><h2 class="st-heading-2">Still Calling It Undervalued</h2><p>Lee called the token “massively undervalued,” pointing to years of sideways trading. The longer the base, he said, the bigger the breakout. The market, however, shows something different. Bitcoin’s (BTC) dominance has risen to about 57.5%, while Ethereum’s sat near 10.5%.</p><p><a href="https://stocktwits.com/coins/ethereum">Ethereum’s price</a> traded relatively flat over the past 24 hours. On Stocktwits, retail sentiment around Ethereum remained in the ‘bearish’ zone, with chatter at ‘normal’ levels over the last day.</p><h2 class="st-heading-2">Why This Cycle Is Different</h2><p>Lee argued this cycle will outrun past ones because of who was buying. Earlier rallies ran on retail money, first through initial coin offerings and later through non-fungible tokens (NFTs). This time, he said, institutions were building real products on blockchains. Investors “aren’t bullish enough,” he said, and should expect “some monster moves in crypto prices.”</p><h2 class="st-heading-2">Why BitMine Bets On Ethereum</h2><p>Lee pointed to Ethereum’s developer base and its record without downtime. He also warned large banks that ignore crypto. He said firms that fail to build a crypto strategy risk becoming "the National Cash Register (NCRs) and the Microwave Communications, Inc. (MCIs) of this era," referring to two companies he said missed major technology shifts.&nbsp;</p><p><a href="https://stocktwits.com/symbol/BMNR">BMNR stock</a> closed little changed on Friday. On Stocktwits, retail sentiment around BMNR remained in the ‘bearish’ zone, with chatter at ‘normal’ levels over the past day.</p><p><strong>Read also:&nbsp;</strong><a href="https://stocktwits.com/news-articles/markets/cryptocurrency/aave-jumps-after-citrini-research-bets-defi-tokens-tokenization/cZxTtbZRBnM"><strong>AAVE Jumps After Citrini Research Bets On DeFi Tokens’ $157T Tokenization Opportunity</strong></a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Tom Lee, the chairman of BitMine, speaks during the Fan Meetup at World Flagship Space Seoul on September 25, 2025 in Seoul, South Korea. (Photo by Myunggu Han/Getty Images for BitMine

Ethereum (ETH) held above $2,400 on Saturday after BitMine Immersion Technologies (BMNR) chairman Tom Lee said the token should top $5,000 by year-end, half the level he called a “conservative target” more than a week ago.

Tom Lee’s Ethereum Year-End Call Is Now Half Of What He Called ‘Conservative’ Last Month

BitMine Immersion Technologies Inc

T-REX 2X Long BMNR Daily Target ETF

iShares Ethereum Trust ETF

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Current Price	$15.02
Prev Close	$13.41
Open	$13.09
Dividend Yield	N/A
50-Day Moving Average	$17.87
Beta	N/A
Avg. Volume	5.49M
PE Ratio	N/A

52-Week High	$284.20
52-Week Low	$6.10
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

BMNU Fundamentals